Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity

被引:57
作者
Hutchings, CL [1 ]
Gilbert, SC [1 ]
Hill, AVS [1 ]
Moore, AC [1 ]
机构
[1] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England
基金
英国惠康基金;
关键词
D O I
10.4049/jimmunol.175.1.599
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The presence of both cell-mediated and Immoral immunity is important in protection from and clearance of a number of infectious pathogens. We describe novel vaccine regimens using combinations of plasmid DNA, poxvirus and protein to induce strong Ag-specific T cell and Ab responses simultaneously in a murine model. Intramuscular (i.m.) immunization with plasmid DNA encoding the middle Ag of hepatitis B (DNA) concurrently with a commercial hepatitis B virus (HBV) vaccine (Engerix-B) followed by boosting immunizations with both modified vaccinia virus Ankara (MVA) encoding the middle Ag of HBV and Engerix-B induced high levels of CD4(+) and CD8(+) T cells and high titer Ab responses to hepatitis B surface Ag (HbsAg). Substitution of Engerix-B with adjuvant-free rHBsAg induced similar T cell responses and greatly enhanced Ab levels. Repeated immunizations with recombinant or nourecombinant MVA mixed with Ag induced higher titers of Abs compared with immunization with either Ag or Engerix-B further demonstrating this novel adjuvant effect of MVA. The poxviruses NYVAC, fowlpox (FP9) and ALVAC, and to a lesser extent, adenovirus, also displayed similar adjuvant properties when used in combination with rHBsAg. The use of poxviruses as an adjuvant for protein to concurrently induce Ag-specific T cells and Abs could be applied to the development of vaccines for many diseases, including HIV and malaria, where both cell mediated and Immoral immunity may be important for protection.
引用
收藏
页码:599 / 606
页数:8
相关论文
共 50 条
[1]   Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine [J].
Amara, RR ;
Smith, JM ;
Staprans, SI ;
Montefiori, DC ;
Villinger, F ;
Altman, JD ;
O'Neil, SP ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McNicholl, JM ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (12) :6138-6146
[2]   Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus [J].
Anderson, RJ ;
Hannan, CM ;
Gilbert, SC ;
Laidlaw, SM ;
Sheu, EG ;
Korten, S ;
Sinden, R ;
Butcher, GA ;
Skinner, MA ;
Hill, AVS .
JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3094-3100
[3]   Liposomal meningococcal B vaccination: Role of dendritic cell targeting in the development of a protective immune response [J].
Arigita, C ;
Bevaart, L ;
Everse, LA ;
Koning, GA ;
Hennink, WE ;
Crommelin, DJA ;
van de Winkel, JGJ ;
van Vugt, MJ ;
Kersten, GFA ;
Jiskoot, W .
INFECTION AND IMMUNITY, 2003, 71 (09) :5210-5218
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines [J].
Barouch, DH ;
McKay, PF ;
Sumida, SM ;
Santra, S ;
Jackson, SS ;
Gorgone, DA ;
Lifton, MA ;
Chakrabarti, BK ;
Xu, L ;
Nabel, GJ ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2003, 77 (16) :8729-8735
[6]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[7]   Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction [J].
Behboudi, S ;
Moore, A ;
Gilbert, SC ;
Nicoll, CL ;
Hill, AVS .
VACCINE, 2004, 22 (31-32) :4326-4331
[8]   HLA CLASS-I-RESTRICTED HUMAN CYTOTOXIC T-CELLS RECOGNIZE ENDOGENOUSLY SYNTHESIZED HEPATITIS-B VIRUS NUCLEOCAPSID ANTIGEN [J].
BERTOLETTI, A ;
FERRARI, C ;
FIACCADORI, F ;
PENNA, A ;
MARGOLSKEE, R ;
SCHLICHT, HJ ;
FOWLER, P ;
GUILHOT, S ;
CHISARI, FV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10445-10449
[9]   Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].
Blanchard, TJ ;
Alcamí, A ;
Andrea, P ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167
[10]   Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations [J].
Boudet, F ;
Chevalier, M ;
Jourdier, TM ;
Tartaglia, J ;
Moste, C .
VACCINE, 2001, 19 (30) :4267-4275